It's been a heady January for biopharma financings, but talk of frothy markets is certain to escalate after Solid Biosciences Inc. salvaged its offering with some fancy footwork, pricing 7.8 million common shares at $16 apiece to gross $125 million. Solid, of Cambridge, Mass., originally planned to offer 5.9 million shares priced in a range of $16 to $18, setting its sights on a raise of about $100 million.